Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy
- 31 January 2003
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 40 (1), 4-12
- https://doi.org/10.1016/s0037-1963(03)70038-9
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferonBritish Journal of Haematology, 2000
- Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-Blood, 1998
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJNCI Journal of the National Cancer Institute, 1998
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phaseBlood, 1995
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- CHRONIC MYELOGENOUS LEUKEMIAJAMA, 1924